Hull RD, Raskob GE, Hirsh J et al (1986) Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. New Engl J Med 315:1109–1114
PubMed
CAS
Article
Google Scholar
Hommes DW, Bura A, Mazzolai L, Buller HR, ten Cate JW (1992) Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Ann Intern Med 116:279–284
PubMed
CAS
Article
Google Scholar
Prandoni P, Carnovali M, Marchiori A (2004) Subcutaneous adjusted-dose unfractionated heparin vs fixed- dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Arch Intern Med 164:1077–1083
PubMed
CAS
Article
Google Scholar
Kearon C, Ginsberg JS, Julian JA et al (2006) Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 296:935–942
PubMed
CAS
Article
Google Scholar
Hyers TM, Hull RD, Weg JG (1989) Antithrombotic therapy for venous thromboembolic disease. Chest 95(2 Suppl):37S–51S
PubMed
CAS
Article
Google Scholar
Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S (1993) The weight-based heparin dosing nomogram compared with a “standard care” nomogram. A randomized controlled trial. Ann Intern Med 119:874–881
PubMed
CAS
Article
Google Scholar
Cuker A (2012) Unfractionated heparin for the treatment of venous thromboembolism: best practices and areas of uncertainty. Semin Thromb Haemost 38:593–599
CAS
Article
Google Scholar
Hyers TM, Hull RD, Weg JG (1992) Antithrombotic therapy for venous thromboembolic disease. Chest 102(4 Suppl):408S–425S
PubMed
CAS
Article
Google Scholar
Hyers TM, Hull RD, Weg JG (1995) Antithrombotic therapy for venous thromboembolic disease. Chest 108(4 Suppl):335S–351S
PubMed
CAS
Article
Google Scholar
Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE (2004) Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(3 Suppl):401S–428S
Kearon C, Akl E, Comerota AJ et al (2012) Antithrombotic therapy and prevention of thrombosis for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2)(Suppl):e419S–e494s
Garcia DA, Baglin TP, Weitz JI, Samama MM (2012) Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2)(Suppl): e24S–e43S
The Joint Commission. National Patient Safety Goals Effective January 1, 2014, Hospital Accreditation Program. http://www.jointcommission.org/assets/1/6/HAP_NPSG_Chapter_2014.pdf. Accessed July 19, 2014
Cippole RJ, Rodvold KA (1992) Heparin. In: Evans WE, Schentag JJ, Jusko WJ (eds) Applied pharmacokinetics: principles of therapeutic drug monitoring. Applied Therapeutics, Vancouver, pp 1–39
Myzienski AE, Lutz MF, Smyth MA (2010) Unfractionated heparin dosing for venous thromboembolism in morbidly obese patients: case report and review of the literature. Pharmacotherapy 30:324
PubMed
Article
Google Scholar
Barletta JF, DeYoung JL, McAllen K, Baker R, Pendleton K (2008) Limitations of a standardized weight-based nomogram for heparin dosing in patients with morbid obesity. Surg Obes Relat Dis 4:748–753
PubMed
Article
Google Scholar
Barba R, Marco J, Martin-Alvarez H et al (2005) The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE). J Thromb Haemost 3:856–862
PubMed
CAS
Article
Google Scholar
Eikelboom JW, Hirsh J (2006) Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost 96:547–552
PubMed
CAS
Google Scholar
Cuker A, Raby A, Moffat KA, Flynn G, Crowther MA (2010) Interlaboratory variation in heparin monitoring: lessons from the quality management program of Ontario coagulation surveys. Thromb Haemost 104:837–844
PubMed
CAS
Article
Google Scholar
Vandiver JW, Vondracek TG (2012) Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy 32:546–558
PubMed
CAS
Article
Google Scholar
Smythe MA, Koerber JM, Westley SJ et al (2001) Use of the activated partial thromboplastin time for heparin monitoring. Am J Clin Pathol 115:148–155
PubMed
CAS
Article
Google Scholar
Price EA, Jin J, Nguyen H, Krishnan G, Bowen R, Zehnder J (2013) Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin. Ann Pharmacotherapy 47:151–158
Article
CAS
Google Scholar
CAP Hematology and Coagulation Checklist, CAP Accreditation Program, 9.25.2102. http://www.cap.org/apps/docs/laboratory_accreditation/sample_checklist.pdf.
Olson JD, Arkin CF, Brandt JT et al (1998) College of American pathologists conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 122:782–798
PubMed
CAS
Google Scholar
Basu D, Gallus A, Hirsh J, Cade J (1972) A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. New Engl J Med 287:324–327
PubMed
CAS
Article
Google Scholar
Chiu HM, Hirsh J, Yung WL, Regoeczi E, Gent M (1977) Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 49:171–184
PubMed
CAS
Google Scholar
Anand S, Ginsberg JS, Kearon C, Gent M, Hirsh J (1996) The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Arch Intern Med 156:1677–1681
PubMed
CAS
Article
Google Scholar
Hull RD, Raskob GE, Rosenbloom D et al (1992) Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 152:1589–1595
PubMed
CAS
Article
Google Scholar
Smythe MA, Mattson JC, Koerber JM (2002) The heparin anti-Xa therapeutic range: are we there yet? Chest 121:303–304
PubMed
Article
Google Scholar
Rosborough TK, Shepherd MF (2004) Achieving target antifactor Xa activity with a heparin protocol based on sex, age, height, and weight. Pharmacotherapy 24:713–719
PubMed
CAS
Article
Google Scholar
Levine MN, Hirsh J, Gent M et al (1994) A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 154:49–56
PubMed
CAS
Article
Google Scholar
Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ (2008) Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133(6 Suppl):454S–545S
PubMed
CAS
Article
Google Scholar
Hyers TM, Agnelli G, Hull RD et al (1998) Antithrombotic therapy for venous thromboembolic disease. Chest 114(5 Suppl):561S–578S
PubMed
CAS
Article
Google Scholar
Raschke RA, Guidry JR, Foley MR (2000) Apparent heparin resistance from elevated factor VIII levels during pregnancy. Obstet Gynecol 96:804–808
PubMed
CAS
Article
Google Scholar
Dobesh PP (2004) Unfractionated heparin dosing nomograms: road maps to where? Pharmacotherapy 24(8 Pt 2):142S–145S
PubMed
CAS
Article
Google Scholar
Hyers TM (2003) Management of venous thromboembolism: past, present, and future. Arch Intern Med 163:759–768
PubMed
CAS
Article
Google Scholar
Hylek EM, Regan S, Henault LE et al (2003) Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis. Arch Intern Med 163:621–627
PubMed
Article
Google Scholar
Cruickshank MK, Levine MN, Hirsh J, Roberts R, Siguenza M (1991) A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 151:333–337
PubMed
CAS
Article
Google Scholar
Smith ML, Wheeler KE (2010) Weight-based heparin protocol using antifactor Xa monitoring. Am J Health System Pharm 67:371–374
CAS
Article
Google Scholar
Brandjes DP, Heijboer H, Buller HR, de Rijk M, Jagt H, ten Cate JW (1992) Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. New Engl J Med 327:1485–1489
PubMed
CAS
Article
Google Scholar
Hyers TM, Agnelli G, Hull RD et al (2001) Antithrombotic therapy for venous thromboembolic disease. Chest 119(1 Suppl):176S–193S
PubMed
CAS
Article
Google Scholar
Houman Fekrazad M, Lopes RD, Stashenko GJ, Alexander JH, Garcia D (2009) Treatment of venous thromboembolism: guidelines translated for the clinician. J Thromb Thrombolysis 28:270–275
PubMed
CAS
Article
Google Scholar
Merli G, Spiro TE, Olsson CG et al (2001) Enoxaparin clinical trial group. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboemobolic disease. Ann Intern Med 134:191–202
PubMed
CAS
Article
Google Scholar
Hull RD, Raskob GE, Brant RF et al (2000) Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med 160:229–236
PubMed
CAS
Article
Google Scholar
Simonneau G, Sors H, Charbonnier B et al (1997) A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: evaluations dans l’Embolie Pulmonaire. New Engl J Med 337:663–669
PubMed
CAS
Article
Google Scholar
The Joint Commission. Specification Manual for national Hospital Inpatient Quality Measures. http://jointcommission.org/spefication_manual_for_national_hospital_inpatient_quality_measures. Accessed Jan 29 2015
Buller HR, Decousus H, Grosso MA et al (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New Engl J Med 369:1406–1415
PubMed
Article
CAS
Google Scholar
Weitz J, Eikelboom JW, Samama MM (2012) New antithrombotic drugs antithrombotic therapy and prevention of thrombosis, 9th ed American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 suppl):e120s–e151s
PubMed
PubMed Central
CAS
Google Scholar
Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342–2352
PubMed
CAS
Article
Google Scholar
Schulman S, Kakkar AK, Goldhaber SZ et al (2014) Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129:764–772
PubMed
CAS
Article
Google Scholar
Bauersachs R, Berkowitz SD, Brenner B et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499–2510
PubMed
CAS
Article
Google Scholar
Buller HR, Prins MH, Lensing AW et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287–1297
PubMed
Article
Google Scholar
Agnelli G, Buller HR, Cohen A et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. New Engl J Med 369:799–808
PubMed
CAS
Article
Google Scholar
Crowther MA, Warkentin TE (2008) Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 111:4871–4879
PubMed
CAS
Article
Google Scholar
Cuker A (2012) Update in the diagnosis and management of heparin-induced thrombocytopenia. Clin Adv Hem Onc 10:453–455
Google Scholar
Smythe MA, Koerber JM, Mehta TP et al (2012) Assessing the impact of a heparin-induced thrombocytopenia protocol on patient management, outcomes and cost. Thromb Haemost 108:992–998
PubMed
CAS
Article
Google Scholar
Lovenox(R) [package insert]. Bridgewater, NJ: Sanofi-Aventis; 2013
Fragmin(R) [package insert]. New York, NY: Pfizer; 2014
Nutescu EA, Spinler SA, Wittkowsky A, Dager WE (2009) Low-molecular weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 43:1064–1083
PubMed
CAS
Article
Google Scholar
Meisner AB, Trewet CB (2012) Clarification of once-daily low molecular weight heparin dose in pulmonary embolism. Chest 142:1074–1075
Article
Google Scholar
Lindmarker P, Holmstrom M (1996) Use of low molecular weight heparin (dalteparin) once daily for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish venous thrombosis dalteparin trial group. J Intern Med 240:395401
Article
Google Scholar
Fiessinger JN, Lopez-Fernandez M, Gatterer E et al (1996) Once daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 76:195–199
PubMed
CAS
Google Scholar
Linkins L-A et al (2012) Treatment and prevention of heparin-induced thrombocytopenia. 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(Suppl):e495S–e530S
PubMed
PubMed Central
CAS
Article
Google Scholar
Wilson SJ, Wilbur K, Burton E, Anderson DR (2001) Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis 31:43–48
Google Scholar
Spinler SA, Dobesh P (2005) Dose capping enoxaparin is unjustified and denies patients with acute coronary syndromes a potentially effective treatment. Chest 127:2288–2290
PubMed
Article
Google Scholar
Ferguson JJ, Califf RM, Antman EM et al (2004) Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292:55–64
Article
Google Scholar
Hagopian JC, Riney JN, Hollands JM, Deal EN (2013) Assessment of bleeding events associated with short- duration therapeutic enoxaparin use in morbidly obese. Ann Pharmacotherapy 47:1641–1648
Article
CAS
Google Scholar
Al Yaseen E, Wells PS, Anderson J, Martin J, Kovacs MJ (2005) The safety of dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. J Thromb Haemost 3:100–102
PubMed
CAS
Article
Google Scholar
Lee AY, Levine MN, Baker RI et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146–153
PubMed
CAS
Article
Google Scholar
Bazinet A, Almanric K, Brunet C et al (2005) Dosage of enoxaparin among obese and renal impairment patients. Thromb Res 116:41–50
PubMed
CAS
Article
Google Scholar
Goudable C, Saivin S, Houin G et al (1991) Pharmacokinetics of a low-molecular weight heparin (Fraxiparine) in various stages of chronic renal failure. Nephron 59:543–545
PubMed
CAS
Article
Google Scholar
Lim W, Dentali F, Eikelboom JW, Crowther MA (2006) Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 144(9):673–684
PubMed
CAS
Article
Google Scholar
Polkinghorne KR, McMahon LP, Becker GJ (2002) Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane) and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. Am J Kidney Dis 40:990–995
PubMed
CAS
Article
Google Scholar
Lachish T, Rudensky B, Slotki I, Zevin S (2007) Enoxaparin dosage adjustment in patients with severe renal failure: antifactor xa concentrations and safety. Pharmacotherapy 27:1347–1352
PubMed
CAS
Article
Google Scholar
Shprecher AR, Cheng-Lai A, Madsen EM et al (2005) Peak antifactor xa activity produced by dalteparin treatement in patients with renal impairment compared with controls. Pharmacotherapy 25:817–822
PubMed
CAS
Article
Google Scholar
Falga C, Capdevila JA, Soler S et al (2007) Clinical outcomes of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry. Thromb Haem 98:771–776
DeCarolis DD, Thorson JG, Clairmont MA et al (2012) Enoxaparin outcomes in patients with moderate renal impairment. Arch Intern Med 172(22):1713–1718
PubMed
CAS
Article
Google Scholar
Favaloro EJ, Bonar R, Aboud M et al. How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective. Lab Hematol 11:157–162
Laposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC (1998) College of American pathologists conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 122:799–807
PubMed
CAS
Google Scholar
Albada J, Nieuwenhuis HK, Sixma JJ (1989) Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study. Circulation 80:935–940
PubMed
CAS
Article
Google Scholar
Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ (1991) Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 78:2337–2343
PubMed
CAS
Google Scholar
Hirsh J, Warkentin TE, Shaughnessy SG et al (2001) Heparin and low-molecular weight heparin: mechanism of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest 119:1(Suppl) 64S–95S
Lim W (2010) Using low molecular weight heparin in special patient populations. J Thromb Thombolysis 29:233–240
CAS
Article
Google Scholar
Ma JM, Jackevicius CA, Yeo E (2004) Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease. Ann Pharmacother 38:1576–1581
PubMed
CAS
Article
Google Scholar
Andras A, Sala Tenna A, Crawford E (2012) Vitamin K antagonists or low molecular weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochran Database Syst Rev 10:CD002001
Otheino R, Abu Affan M, Okpo E (2007) Home versus in-patient treatment of deep vein thombosis. Cochran Database Syst Rev 3:CD003076
Piran S, Le Gal G, Wells PS et al (2013) Outpatient treatment of symptomatic pulmonary embolism: a systematic review and meta-analysis. Thromb Res 132:515–519
PubMed
CAS
Article
Google Scholar
Baglin T (2010) Fifty per cent of patients with pulmonary embolism can be treated as outpatients. J Thromb Haemost 8:2404–2405
PubMed
CAS
Article
Google Scholar
Venetz C, Jiménez D, Mean M, Aujesky D (2011) A comparison of the original and simplified pulmonary embolism severity index. Thromb Haemost 106:423–428
PubMed
CAS
Article
Google Scholar
Aujesky D, Roy PM, Verschuren F et al (2001) Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international open-label, randomized, non-inferiority trial. Lancet 378:41–48
Article
Google Scholar
Trujillo-Santos J, Herrera S, Page MA, Soto MJ et al (2006) Predicting adverse outcomes in outpatients with acute deep vein thrombosis. Findings from the RIETE registry. J Vasc Surg 44:789–793
PubMed
Article
Google Scholar
Winter M, Keelings D, Sharpen F et al (2005) Procedures for the outpatient management of patients with deep venous thrombosis. Clin Lab Haematol 27:61–66
PubMed
CAS
Article
Google Scholar
Van Veen JJ, Maclean RM, Hampton KK et al (2011) Protamine reversal of low molecular weight heparin: clinically effective? Blood Coagul Fibrinolysis 22:565–570
PubMed
Article
CAS
Google Scholar
Monte AA, Bodmer M, Schaeffer TH (2010) Low molecular-weight heparin overdose: management by observation. Ann Pharmacother 44:1836–1839
PubMed
Article
Google Scholar
Crowther MA, Berry LR, Monagle PT, Chan AKC (2002) Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 116:178–186
PubMed
CAS
Article
Google Scholar
Byrne M, Zumberg M (2012) Intentional low-molecular-weight heparin overdose: a case report and review. Blood Coag Fibrinolysis 23:772–774
Article
Google Scholar
The MATTISSE Investigators (2003) Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349:1695–1702
Article
Google Scholar
Buller HR et al (2004) Fondaparinux or enoxaparin for the initial treatment of symptomatic deep vein thrombosis. A randomized trial. Ann Intern Med 140:867–873
PubMed
Article
Google Scholar
Davidson BL et al (2007) Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin for acute venous thromboembolism in the Matisse trials. J Thromb Haemost 5:1191–1194
PubMed
CAS
Article
Google Scholar
Turpie AG et al (2009) Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients. Blood Coagul Fibrinolysis 20:114–121
PubMed
CAS
Article
Google Scholar
Ageno W et al (2012) Safety and efficacy of low-dose fondaparinux (1.5 mg) for the prevention of venous thromboembolism in acutely ill medical patients with renal impairment: the FONDAIR study. J Thromb Haemost 10:2291–2297
PubMed
CAS
Article
Google Scholar
Smogorzewska A et al (2006) Effect of fondaparinux on coagulation assays. Results of the College of American Pathologists proficiency testing. Arch Pathol Lab Med 130:1605–1611
PubMed
CAS
Google Scholar
Paolucci F et al (2003) Two sensitive and rapid chromogenic assays of fondaparinux sodium (Arixtra) in human plasma and other biological matrices. Clin Lab 49:P451–P460
Google Scholar
Depasse F et al (2004) Assessment of three chromogenic and one clotting assay for the measurement of synthetic pentasaccharide fondaparinux (Arixtra) anti-Xa activity. J Thrmob Haemost 2:346–348
CAS
Article
Google Scholar
Klaeffling C et al (2006) Development and clinical evaluation of two chromogenic substrate methods for monitoring fondaparinux sodium. Ther Drug Monit 28:375–381
PubMed
CAS
Article
Google Scholar
Depasse F et al (2000) Anti-Xa monitoring: inter-assay variability. Thromb Haemost 84:1122–1123
PubMed
CAS
Google Scholar
Donat F et al (2002) The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 41(Suppl. 2):39–45
PubMed
Google Scholar
Gehrie E et al (2012) Test of the month: the chromogenic antifactor Xa assay. Am J Hematol 87:194–196
PubMed
CAS
Article
Google Scholar
Savi P et al (2005) Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies; a blinded comparative multicenter study with unfractionated heparin. Blood 105:139–144
PubMed
CAS
Article
Google Scholar
Selling S et al (2007) Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 356:2653–2655
Article
Google Scholar
Rota E et al (2008) Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost 99:779–781
PubMed
CAS
Google Scholar
Alsaleh KA et al (2008) Delayed onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis. Am J Hematol 83:876–878
PubMed
CAS
Article
Google Scholar
Blackmer AB et al (2009) Fondaparinux and the management of heparin-induced thrombocytopenia: the journey continues. Ann Pharmacother 43:1636–1646
PubMed
CAS
Article
Google Scholar
Kovacs MJ, Kuo KHM et al (2005) Fondaparinux: a potential new therapy for HIT. Hematology 10:271–275
PubMed
Article
CAS
Google Scholar
Warkentin TE, Pai M, Sheppard JI et al (2011) Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost 9:2389–2396
PubMed
CAS
Article
Google Scholar
Schindewolf M et al (2014) Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT)—findings from the GerHIT multi-centre registry study. Thomb Res 134:29–35
CAS
Article
Google Scholar
Lobo B et al (2008) Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 99:208–214
PubMed
CAS
Google Scholar
Warkentin TE (2014) Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls. Expert Opin Drug Safety 13:25–43
CAS
Article
Google Scholar
Bernat A et al (1996) Antagonism of SR 90107A/ORG 31540-induced bleeding by protamine sulfate in rats and mice. Thromb Haemost 76:715–719
PubMed
CAS
Google Scholar
Bijsterveld NR et al (2002) Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 106:2550–2554
PubMed
CAS
Article
Google Scholar
Vavra KA et al (2010) Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants. Ann Pharmacother 44:718–726
PubMed
CAS
Article
Google Scholar
Elmer J et al (2012) Emergency reversal of pentasaccharide anticoagulants: a systematic review of the literature. Transfusion Medicine 22:108–115
PubMed
CAS
Article
Google Scholar
Luporsi P et al (2011) Use of recombinant factor VIIa (NovoSeven®) in 8 patients with ongoing life-threatening bleeding treated with fondaparinux. Acute Cardiac Care 13:93–98
PubMed
CAS
Article
Google Scholar
Desmurs-Clavel H et al (2009) Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aCCP, and PCC. Thromb Res 123:796–798
PubMed
CAS
Article
Google Scholar